OPEN END TURBO LONG - ASTRAZENECA | Market Closed - Börse Stuttgart 08:12:59 2024-06-13 am EDT | ||
| 0.97 EUR | -6.73% |
|
| Current month | +61.67% | ||
| 1 month | +5.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 0.97 | -6.73% |
| 24-06-12 | 1.04 | +11.83% |
| 24-06-11 | 0.93 | -18.42% |
| 24-06-10 | 1.14 | -2.56% |
| 24-06-07 | 1.17 | -0.85% |
Delayed Quote Börse Stuttgart
Last update June 13, 2024 at 08:12 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG37WB |
| ISIN | DE000MG37WB1 |
| Date issued | 2024-04-29 |
| Strike | 11,651 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.5 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.1
USD
Average target price
174.4
USD
Spread / Average Target
+10.34%
- Stock Market
- Certificates
- Certificat
